BD in the news

BD will invest $19 billion in the U.S., with $3 billion directly boosting domestic manufacturing of essential medical consumables, in a partnership with the U.S. government.

BD will invest $19 billion in U.S. operations, with over $1 billion for Nebraska manufacturing, to boost domestic medical supply production and secure tariff relief.

BD has promoted Ferass Abuzaina to worldwide president of its Surgery business unit, effective immediately.

BD announced positive nine-month results from its AGILITY trial, showing strong safety and effectiveness for its Revello™ Vascular Covered Stent in treating iliac artery disease.

BD formed a partnership with the Trump administration to invest $19 billion in U.S. manufacturing to expand production of medical consumables and strengthen the domestic supply chain.

BD is partnering with the U.S. government, investing $19 billion, to significantly expand domestic manufacturing of essential medical consumables and strengthen the supply chain.

BD's Advanced Patient Monitoring division held its second annual Patient Day, where patients shared their stories to inspire and reconnect employees with the purpose of their work.

BD will invest $19 billion in the U.S., including $3 billion for manufacturing expansion, to increase domestic production of medical consumables and secure tariff relief.

BD will invest billions in U.S. manufacturing in exchange for tariff relief from the Trump administration.

BD Alaris Infusion Pump Sets are under a Class I recall due to worse performance than previously disclosed.

BD appointed Ferass Abuzaina as Worldwide President of its Surgery business unit, responsible for global strategic, operational, and commercial performance.

Supradeep Vankayala, a lead design engineer, developed a sustainable, PFAS-free packaging solution and prevented significant product waste, earning him a CPG NexGen award.

BD celebrated 70 years of manufacturing at its Sandy, Utah, facility, which produces medical catheters and components.

BD's Sandy, Utah, manufacturing facility celebrates 70 years of producing critical medical technologies, including IV catheters, with significant investments and a focus on community engagement.

BD's Utah IV catheters plant marks 70 years, producing billions of components and hundreds of millions of catheters annually.

Many BD and some NovoFine insulin pen needles are no longer on the NHS Drug Tariff due to a brand transition to embecta, requiring patients to switch to alternative prescribed needles.

BD's Sandy, Utah manufacturing site celebrates 70 years of producing essential medical devices, highlighting its significant contributions to healthcare, innovation, and local community development.

BD's Sandy, Utah plant marked 70 years of manufacturing medical devices, with over 1,000 employees and recent investments exceeding $100 million.

BD's Sandy, Utah manufacturing facility is celebrating 70 years of producing medical devices, with significant investments and community contributions.

BD hired Arthur Hu, a former Lenovo executive, as its new chief information and digital officer to drive digital transformation and AI integration.